The Claim
Inhibition of PCSK9 using monoclonal antibodies such as evolocumab or alirocumab reduces plasma LDL cholesterol levels by approximately 50–60% in patients with hypercholesterolemia. This effect occurs through blocking the extracellular interaction between PCSK9 and the LDL receptor (LDLR) on hepatocytes, which prevents lysosomal degradation of LDLR and enhances its recycling to the cell surface.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A type of medicine (like evolocumab or alirocumab) blocks a protein in your body called PCSK9, which helps your liver remove bad cholesterol from your blood—cutting it by about half.
See the scientific wording
Inhibition of PCSK9 with monoclonal antibodies (evolocumab or alirocumab) reduces plasma LDL cholesterol levels by approximately 50–60% in patients with hypercholesterolemia, and this effect is primarily mediated through blocking the extracellular interaction between PCSK9 and LDLR on hepatocytes, thereby preventing lysosomal degradation of LDLR and increasing its recycling.
What the research says
1 studyStudy: Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
The study says that blocking PCSK9 with special antibodies helps the liver remove bad cholesterol from the blood by saving the receptors that do the cleaning.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.